TriangleAMB-05X (NCT06617858)
AMB-05X trial for Colorectal Cancer (NCT06617858). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with colorectal adenocarcinoma after all planned curative-intent treatment. Scans and clinical assessment must show no detectable cancer, but a Signatera blood test must detect tumor DNA.
The idea: intravenous AMB-05X blocks CSF1R, a signal used by tumor-associated macrophages that can suppress immune responses. Researchers test six months of treatment, measuring tumor-DNA clearance and safety. Testing must occur at least 28 days after standard treatment ends.
This phase 2 study plans 15 patients. Van Morris leads at MD Anderson in Houston, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.